Trial Outcomes & Findings for The Role of Orexin in Human Panic Disorder (NCT NCT02593682)
NCT ID: NCT02593682
Last Updated: 2021-07-02
Results Overview
Change in orexin levels from baseline to +1 min post-CO2 challenge
COMPLETED
PHASE4
3 participants
Baseline and +1 minute post-CO2 challenge
2021-07-02
Participant Flow
Per IRB records, 3 participants enrolled and 2 completed the study. PI left institution and all efforts to locate data have been exhausted.
Participant milestones
| Measure |
Suvorexant Group
In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
suvorexant
|
Placebo Group
In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
placebo
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Role of Orexin in Human Panic Disorder
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Baseline and +1 minute post-CO2 challengePopulation: PI left institution and all efforts to locate data have been exhausted.
Change in orexin levels from baseline to +1 min post-CO2 challenge
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline and +5 minutes post-CO2 challengePopulation: PI left institution and all efforts to locate data have been exhausted.
Change in orexin levels from baseline to +5 min post-CO2 challenge
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline and +15 minutes post-CO2 challengePopulation: PI left institution and all efforts to locate data have been exhausted.
Change in orexin levels from baseline to +15 min post-CO2 challenge
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: Baseline and +60 minutes post-CO2 challengePopulation: PI left institution and all efforts to locate data have been exhausted.
Change in orexin levels from baseline to +60 min post-CO2 challenge
Outcome measures
Outcome data not reported
Adverse Events
Suvorexant Group
Placebo Group
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Andrew Goddard
University of California, San Francisco
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place